Assessment of the Concentrations of Selected Aminothiols in Patients after COVID-19.

Assessment of the Concentrations of Selected Aminothiols in Patients after COVID-19.

Publication date: Jul 14, 2024

Background: Data show that due to endothelial damage and thrombogenic effects, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection may accelerate the development of atherosclerosis and increase the risk of cardiovascular diseases (CVDs). The impaired metabolism of aminothiols increases oxidative stress, as these molecules are involved in antioxidant defense as well as in thiol redox control. In this study, total levels of selected aminothiols (i. e., cysteine (Cys), homocysteine (HCy), and glutathione) in convalescents after coronavirus disease of 2019 (COVID-19) were evaluated. The analyses were made according to the sex of the patients, time from COVID-19 onset, and COVID-19 severity. Methods: The study group consisted of 212 patients after COVID-19. Levels of total aminothiols were assessed in the blood plasma using high-performance liquid chromatography (HPLC). Results: The mean Cys concentrations were higher in men than in women (229. 92 umol/L +/- 51. 54 vs. 210. 35 umol/L +/- 41. 90, respectively; p = 0. 003). Differences in Cys levels were also noticed in the total study group between patients distinguished due to time from disease onset (226. 82 umol/L +/- 40. 57 in 24 weeks; p = 0. 005). In addition, over 11% of total patients 12-24 weeks from disease onset had Cys levels above 300 umol/L compared to almost 4% of patients 24 weeks (p = 0. 046). In sex-adjusted subgroups, significant differences due to time from COVID-19 were found in Cys levels in women (p = 0. 004) and in glutathione levels in men (p = 0. 024). None of the aminothiol levels differed between the subgroups based on the severity of COVID-19. Conclusions: Men had overall higher Cys levels than women. Cys levels were lower >24 weeks after COVID-19 onset than in the earlier period after disease onset. A partial elevation in Cys levels 12-24 weeks after the disease onset may contribute to the increase in CVD risk in the post-COVID-19 period.

Open Access PDF

Concepts Keywords
Atherosclerosis aminothiols
Cardiovascular cardiovascular diseases
Coronavirus COVID-19
Glutathione cysteine
glutathione
homocysteine

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infection
disease MESH atherosclerosis
disease MESH cardiovascular diseases
pathway REACTOME Metabolism
disease MESH oxidative stress
drug DRUGBANK L-Cysteine
drug DRUGBANK Glutathione
pathway KEGG Coronavirus disease
disease VO time
disease MESH Heart Failure
drug DRUGBANK Coenzyme M
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH complications
disease MESH acute coronary syndromes
disease MESH Takotsubo syndrome
disease MESH myocarditis
disease MESH cardiac arrhythmias
disease MESH hypertension
disease MESH postural orthostatic tachycardia syndrome
disease MESH stroke
drug DRUGBANK Angiotensin II
disease MESH inflammation
disease MESH arterial stiffness
drug DRUGBANK Amino acids
drug DRUGBANK Methionine
disease MESH etiology
disease MESH thromboembolism
disease VO frequency
disease VO erythrocyte
disease MESH thrombosis
drug DRUGBANK Folic Acid
pathway KEGG Viral replication
disease MESH cognitive impairment
disease MESH long COVID
disease MESH syndrome
disease MESH convalescence
drug DRUGBANK Tretamine
disease MESH muscle strength
disease IDO process
disease IDO blood
disease MESH hemolysis
disease VO protocol
disease MESH Hypercholesterolemia
drug DRUGBANK Cholesterol
drug DRUGBANK Creatinine

Original Article

(Visited 1 times, 1 visits today)